Plus Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered board elections, auditor ratification, executive compensation, and a stock plan amendment, all of which were approved. Voting procedures were clarified, and a reverse stock split was noted as recently effective.
-
A $15M capital raise extends funding through 2027, supporting clinical and commercial milestones. RIOVA trials advance with FDA-aligned pivotal design, while CNSIDE commercialization targets expanded coverage, increased test volumes, and break-even by 2027.
Fiscal Year 2025
-
CNside is positioned to transform CNS cancer diagnostics with a highly sensitive, patented platform and a $6 billion U.S. market opportunity. Commercial launch begins in Texas in Q3 2025, with national expansion and payer agreements underway. Financial guidance will be updated in Q1 2026.
Fiscal Year 2024
-
Closed $15M equity financing and received $2M in grants, extending cash runway into mid-2026. Advanced Rheobic clinical programs with positive LM data and prepared for CNSide's 2025 commercial launch. Net loss for 2024 was $13M, with key milestones and data readouts expected in 2025.
-
Clinical programs for RNL in LM and GBM advanced with strong safety and efficacy data, while CNSide diagnostic platform is set for commercial launch in early 2025. Financial position is supported by grants, private placement, and expanded manufacturing, with key regulatory and clinical milestones expected through 2025.
-
The conference featured advances in targeted radiotherapeutics for CNS tumors, with clinical programs showing strong safety and efficacy signals. Key milestones include upcoming data readouts, a new diagnostic launch by Q4 2024, and funding secured into 2026.
-
Clinical trials for LM and GBM showed encouraging safety and efficacy signals, with CNSide diagnostics influencing over 90% of treatment decisions and demonstrating superior sensitivity. Cash position remains stable, bolstered by grants and a recent private placement, with multiple data updates and regulatory milestones expected in late 2024.